Background {#Sec1}
==========

Ankylosing spondylitis (AS) is a type of spondyloarthritis in which hallmark clinical features are inflammation at entheses and subchondral bone of the pelvic and spinal joints with subsequent abnormal new bone formation at these sites. Ultimately, this leads to ossification of entheses and joints resulting in loss of joint mobility. The incidence varies between 0.1 and 1.8% with the highest incidence in Scandinavia. Onset is typically in young adults with a male predominance. Medications used include non-steroid anti-inflammatory drugs (NSAIDs), and biological disease-modifying anti-rheumatic drugs (bDMARDs), i.e. tumor necrosis factor-α inhibitors (anti-TNF) and more recently also an interleukin(IL)-17A inhibitor (secukinumab) \[[@CR1]\].

The cause of AS is unknown but is believed to involve a combination of genetic and environmental factors \[[@CR2]\]. The heritability is polygenic and estimated to exceed 90%, with the HLA-B27 allele as the major contributor accounting for approximately 25% of the heritability of AS \[[@CR2]\]. The IL-17/ IL-23 pathway and the TNF-α pathway are central in the pathogenesis of AS and alterations in these pathways have been shown in mouse models to affect development and severity of enthesitis \[[@CR3], [@CR4]\].

TNF-α can be activated by Pathogen-Associated Molecular Patterns (PAMPs) such as bacterial or viral DNA, flagellin, or lipopolysaccharide (LPS), through the NFkB pathway. PAMPs can be recognized by Toll-like receptors (TLRs) thereby initiating a kinase cascade which phosphorylates and degrades the NFkB inhibitor IkBα \[[@CR5]\]. This releases NFkB which is transported from the cytosol to the nucleus where it initiates expression of pro- and anti-inflammatory cytokines including TNF-α and IL-17 (<http://www.bu.edu/nf-kb/gene-resources/target-genes/>). The TNF-α and NFkB pathway are intertwined and TNF-α can feedback stimulate NFkB by binding to TNF receptors (TNFR1 or TNFR2), resulting in a kinase cascade similar to, but distinct from, the pathway induced by TLRs \[[@CR5]\].

The IL23/IL17 pathway can also stimulate TNF-α activity. The pro-inflammatory cytokine IL-17 enhances the production of other pro-inflammatory cytokines including TNF-α, and the secretion IL-17 itself can be enhanced by IL-23 \[[@CR6]\].

PAMPs can also be recognized by intracellular Nod-like receptors (NLRs). In turn, NLRs can activate pro-inflammatory cytokines including IL-18 \[[@CR7]\]. IL-18 is invloved in the IL23/IL17 pathway and can enhance the production of IL-17 \[[@CR8]\].

The aim of this study was to assess whether functional single nucleotide polymorphisms.

(SNPs) in genes involved in the TNF-α, IL23/IL17, NFkB, and other pro- and anti-inflammatory pathways were associated with risk of AS.

Methods {#Sec2}
=======

Patients and samples {#Sec3}
--------------------

The DANBIO registry includes prospectively collected clinical data on patients with inflammatory joint diseases including smoking status, disease characteristics e.g. HLA-B27 status, disease activity, treatment, and treatment outcomes. Patients from all of Denmark are monitored in routine care during treatment with conventional and biologic disease modifying anti-rheumatic drugs (bDMARDs) \[[@CR9]\].

Screening for tuberculosis before initiation of treatment with biological drugs is routinely performed in Denmark. Left over blood clots (after whole blood analysis for *Mycobacterium tuberculosis*) were collected from all patients screened for tuberculosis at Statens Serum Institut (Copenhagen, Denmark) from 01.09.2009 to 31.01.2013; the Department of Respiratory Diseases B and the Department of Clinical Microbiology, Aarhus University Hospital (Aarhus, Denmark) from 01.01.2011 to 31.01.2014; the Department of Clinical Biochemistry, Herlev and Gentofte Hospital (Hellerup, Denmark) from 01.03.2012 to 31.01.2014; the Department of Biochemistry, Hospital of Lillebaelt (Vejle, Denmark); and the Department of Biochemistry, Hospital of Slagelse (Slagelse, Denmark) from 01.01.2014 to 31.01.2014. Furthermore, from 01.01.2013 to 31.12.2013 blood samples were collected from all patients with AS treated with or without anti-TNF drugs at the Department of Rheumatology, Frederiksberg Hospital (Frederiksberg, Denmark).

By linking the unique personal identification number of Danish citizens (CPR-number) from each blood sample with the clinical data from DANBIO, 709 patients with AS (ICD-10: M45.9) were identified. The control group consisted of 795 healthy blood donors recruited from Viborg, Denmark.

Genotyping {#Sec4}
----------

Fifty-one SNPs in genes involved in the TNF-α, IL23/IL17, NFκB, and other pro- and anti-inflammatory pathways were assessed. A list of all SNPs studied and genotype distribution is presented in Table [1](#Tab1){ref-type="table"} and SNPs associated with AS are summarized in Table [2](#Tab2){ref-type="table"}.Table 1Odds ratios (OR) and 95% confidence interval (95CI) for genotypes studied among healthy controls and patients with ankylosing spondylitis (AS)Gene\
rs-numberHealthy controlsASUnadjustedAdjusted, age & sexAdjusted, age, sex & smokingOR (95 CI)*p*OR (9 5CI)*p*OR (95 CI)*pTLR1*\
rs4833095 TT485415 TC2612381.07 (0.86--1.33)0.571.03 (0.82--1.29)0.831.05 (0.78--1.42)0.73 CC20432.51 (1.45--4.34)0.000952.59 (1.48--4.51)0.000812.86 (1.44--5.68)0.0026 TC or CC2812811.17 (0.95--1.44)0.151.14 (0.91--1.41)0.251.18 (0.89--1.58)0.26*TLR2*\
rs3804099 TT241197 TC3933541.10 (0.87--1.40)0.421.07 (0.84--1.37)0.581.02 (0.73--1.42)0.90 CC1441421.21 (0.89--1.63)0.221.24 (0.91--1.68)0.171.30 (0.87--1.96)0.20 TC or CC5374961.13 (0.90--1.41)0.291.11 (0.89--1.40)0.361.10 (0.80--1.50)0.57*TLR2*\
rs11938228 CC327314 CA3683130.89 (0.71--1.10)0.270.86 (0.69--1.07)0.170.80 (0.60--1.08)0.15 AA76690.95 (0.66--1.36)0.760.92 (0.63--1.33)0.661.03 (0.62--1.69)0.92 CA or AA4443820.90 (0.73--1.10)0.300.87 (0.70--1.07)0.190.84 (0.63--1.11)0.22*TLR2*\
rs4696480 AA199179 AT4173480.93 (0.72--1.19)0.550.89 (0.69--1.15)0.380.84 (0.60--1.18)0.31 TT1551691.21 (0.90--1.63)0.201.16 (0.86--1.58)0.331.18 (0.78--1.78)0.44 AT or TT5725171.00 (0.79--1.27)0.970.97 (0.76--1.23)0.780.92 (0.67--1.27)0.62*TLR4*\
rs5030728 GG359322 GA3232981.03 (0.83--1.28)0.801.01 (0.81--1.27)0.910.93 (0.69--1.25)0.62 AA78701.00 (0.70--1.43)1.000.98 (0.68--1.42)0.930.87 (0.53--1.42)0.57 GA or AA4013681.02 (0.83--1.26)0.831.01 (0.82--1.25)0.940.91 (0.69--1.21)0.53*TLR4*\
rs1554973 TT440395 TC2722611.07 (0.86--1.33)0.551.06 (0.85--1.32)0.620.98 (0.73--1.32)0.90 CC62330.59 (0.38--0.92)0.020.55 (0.34--0.86)0.010.68 (0.38--1.23)0.20 TC or CC3342940.98 (0.80--1.21)0.850.96 (0.78--1.19)0.720.93 (0.70--1.24)0.63*TLR4*\
rs12377632 TT306271 TC3583191.01 (0.81--1.26)0.961.05 (0.84--1.32)0.661.07 (0.78--1.46)0.67 CC102961.06 (0.77--1.47)0.711.11 (0.80--1.55)0.521.41 (0.92--2.17)0.12 TC or CC4604151.02 (0.83--1.26)0.861.06 (0.86--1.32)0.581.14 (0.85--1.53)0.37*TLR5*\
rs5744168 CC672605 CT94891.05 (0.77--1.43)0.751.05 (0.77--1.45)0.740.89 (0.58--1.37)0.60 TT520.44 (0.09--2.30)0.330.45 (0.08--2.43)0.350.04 (0.00--3.54)0.16 CT or TT99911.02 (0.75--1.39)0.891.02 (0.75--1.40)0.880.84 (0.55--1.29)0.43*TLR5*\
rs5744174 TT215216 TC3993370.84 (0.66--1.07)0.150.85 (0.67--1.09)0.200.82 (0.60--1.14)0.24 CC1441380.95 (0.71--1.29)0.761.02 (0.75--1.39)0.910.87 (0.57--1.32)0.51 TC or CC5434750.87 (0.69--1.09)0.230.90 (0.71--1.13)0.360.84 (0.62--1.14)0.26*TLR9*\
rs187084 TT262237 TC3663351.01 (0.80--1.27)0.921.03 (0.82--1.31)0.781.09 (0.79--1.50)0.60 CC1421200.93 (0.69--1.26)0.660.91 (0.67--1.24)0.561.07 (0.71--1.61)0.76 TC or CC5084550.99 (0.80--1.23)0.931.00 (0.80--1.25)0.981.08 (0.80--1.46)0.60*TLR9*\
rs352139 GG255211 GA3473241.13 (0.89--1.43)0.321.08 (0.85--1.38)0.521.01 (0.73--1.40)0.93 AA1671391.01 (0.75--1.34)0.970.96 (0.71--1.30)0.790.80 (0.53--1.20)0.27 GA or AA5144631.09 (0.87--1.36)0.451.04 (0.83--1.31)0.720.94 (0.69--1.27)0.68*LY96*\
rs11465996 CC344341 CG3372980.89 (0.72--1.11)0.300.91 (0.73--1.14)0.420.89 (0.66--1.20)0.45 GG81530.66 (0.45--0.96)0.030.68 (0.46--1.00)0.04980.65 (0.39--1.10)0.11 CG or GG4183510.85 (0.69--1.04)0.110.87 (0.70--1.07)0.180.84 (0.63--1.12)0.24*CD14*\
Rs2569190 GG236194 GA3603391.15 (0.90--1.46)0.271.18 (0.92--1.51)0.191.27 (0.91--1.78)0.16 AA1701571.12 (0.84--1.50)0.431.20 (0.89--1.61)0.241.46 (0.98--2.19)0.06 GA or AA5304961.14 (0.91--1.43)0.261.18 (0.94--1.50)0.151.32 (0.96--1.82)0.08*TIRAP*\
rs8177374 CC556521 CT1851590.92 (0.72--1.17)0.490.99 (0.77--1.27)0.941.38 (0.99--1.91)0.06 TT21150.76 (0.39--1.49)0.430.76 (0.38--1.53)0.451.31 (0.55--3.12)0.55 CT or TT2061740.90 (0.71--1.14)0.390.97 (0.76--1.23)0.811.38 (1.00--1.89)0.047*SUMO4*\
rs237025 TT215195 TC3623581.09 (0.86--1.39)0.481.08 (0.84--1.38)0.551.04 (0.75--1.44)0.80 CC1951360.77 (0.57--1.03)0.080.75 (0.55--1.01)0.060.55 (0.36--0.84)0.01 TC or CC5574940.98 (0.78--1.23)0.850.96 (0.76--1.22)0.750.87 (0.64--1.19)0.38*NFKBIA*\
rs696 GG298259 GA3663361.06 (0.85--1.32)0.631.06 (0.84--1.33)0.641.02 (0.75--1.39)0.88 AA101901.03 (0.74--1.43)0.880.97 (0.69--1.36)0.861.07 (0.67--1.69)0.78 GA or AA4674261.05 (0.85--1.30)0.651.04 (0.84--1.29)0.731.03 (0.77--1.38)0.84*NFKB1*\
rs28362491 Ins/Ins269258 Ins/−3763160.88 (0.70--1.10)0.250.89 (0.70--1.12)0.310.74 (0.54--1.01)0.06 −/−1221000.85 (0.62--1.17)0.330.82 (0.59--1.13)0.220.78 (0.51--1.19)0.25 Ins/− or −/−4984160.87 (0.70--1.08)0.210.87 (0.70--1.08)0.210.75 (0.56--1.01)0.06*TNF*\
rs1800629 GG527549 GA2231290.56 (0.43--0.71)0.00000320.58 (0.45--0.75)0.0000290.63 (0.45--0.89)0.01 AA2590.35 (0.16--0.75)0.010.39 (0.18--0.85)0.020.19 (0.04--0.79)0.02 GA or AA2481380.53 (0.42--0.68)0.000000300.56 (0.44--0.72)0.00000470.59 (0.42--0.82)0.0018*TNF*\
rs361525 GG708669 GA60300.53 (0.34--0.83)0.010.52 (0.32--0.82)0.00490.61 (0.33--1.12)0.11 AA301.00 (1.00--1.00)1.001.00 (1.00--1.00)1.001.00 (1.00--1.00)1.00 GA or AA63300.50 (0.32--0.79)0.00270.49 (0.31--0.78)0.00240.58 (0.32--1.05)0.07*TNFRSF1A*\
rs4149570 GG307217 GT3553391.35 (1.07--1.70)0.011.33 (1.05--1.68)0.021.46 (1.06--2.00)0.02 TT1091321.71 (1.26--2.33)0.000601.79 (1.31--2.46)0.000272.26 (1.48--3.47)0.00017 GT or TT4644711.44 (1.16--1.78)0.00101.44 (1.15--1.80)0.00131.64 (1.21--2.22)0.0014*TNFAIP3*\
rs6927172 CC473415 CG2642451.06 (0.85--1.32)0.611.06 (0.85--1.33)0.611.03 (0.76--1.39)0.85 GG40250.71 (0.42--1.19)0.200.70 (0.41--1.19)0.180.51 (0.23--1.10)0.09 CG or GG3042701.01 (0.82--1.25)0.911.01 (0.82--1.26)0.910.95 (0.71--1.27)0.73*TGFB1*\
rs1800469 CC383344 CT2972991.12 (0.90--1.39)0.301.08 (0.87--1.35)0.481.28 (0.95--1.71)0.11 TT86530.69 (0.47--1.00)0.0470.69 (0.47--1.02)0.060.69 (0.40--1.17)0.17 CT or TT3833521.02 (0.83--1.26)0.831.00 (0.81--1.23)0.971.14 (0.86--1.52)0.35*PTPN22*\
rs2476601 GG588557 GA1661220.78 (0.60--1.01)0.060.77 (0.59--1.00)0.050.75 (0.52--1.09)0.13 AA1160.58 (0.21--1.57)0.280.57 (0.20--1.58)0.280.83 (0.21--3.28)0.80 GA or AA1771280.76 (0.59--0.99)0.040.76 (0.58--0.98)0.040.76 (0.53--1.09)0.13*PPARG*\
rs1801282 CC548511 CG2071670.87 (0.68--1.10)0.230.85 (0.66--1.08)0.180.87 (0.63--1.21)0.42 GG14151.15 (0.55--2.40)0.711.33 (0.62--2.83)0.461.54 (0.60--3.98)0.37 CG or GG2211820.88 (0.70--1.11)0.290.88 (0.69--1.11)0.270.91 (0.67--1.26)0.58*IL1B*\
rs4848306 GG246215 GA3733521.08 (0.85--1.36)0.521.09 (0.86--1.39)0.481.16 (0.84--1.60)0.38 AA1511250.95 (0.70--1.28)0.720.96 (0.71--1.31)0.810.88 (0.57--1.34)0.55 GA or AA5244771.04 (0.83--1.30)0.721.06 (0.84--1.33)0.641.08 (0.79--1.46)0.64*IL1B*\
rs1143623 GG401365 GC3162780.97 (0.78--1.20)0.760.98 (0.79--1.22)0.871.07 (0.80--1.44)0.66 CC55521.04 (0.69--1.56)0.851.12 (0.74--1.69)0.590.87 (0.48--1.57)0.64 GC or CC3713300.98 (0.80--1.20)0.831.00 (0.81--1.24)0.981.04 (0.78--1.38)0.79*IL1B*\
rs1143627 TT340305 TC3393051.00 (0.81--1.25)0.981.00 (0.79--1.25)0.971.05 (0.78--1.42)0.75 CC97860.99 (0.71--1.37)0.941.01 (0.72--1.41)0.950.85 (0.53--1.36)0.50 TC or CC4363911.00 (0.81--1.23)1.001.00 (0.81--1.24)1.001.00 (0.76--1.34)0.97*IL1RN*\
rs4251961 TT298247 TC3603241.09 (0.87--1.36)0.471.04 (0.83--1.32)0.711.22 (0.89--1.67)0.21 CC1121051.13 (0.83--1.55)0.441.05 (0.76--1.46)0.761.41 (0.92--2.17)0.12 TC or CC4724291.10 (0.89--1.36)0.401.05 (0.84--1.30)0.681.26 (0.94--1.71)0.12*IL4R*\
rs1805010 AA209201 AG4103170.80 (0.63--1.02)0.080.79 (0.62--1.02)0.070.73 (0.52--1.02)0.07 GG1571330.88 (0.65--1.19)0.410.91 (0.67--1.24)0.550.87 (0.58--1.33)0.53 AG or GG5674500.83 (0.66--1.04)0.100.83 (0.65--1.05)0.120.77 (0.56--1.06)0.11*IL6*\
rs10499563 TT476439 TC2592250.94 (0.76--1.17)0.600.94 (0.75--1.18)0.600.77 (0.57--1.05)0.10 CC35260.81 (0.48--1.36)0.420.72 (0.42--1.25)0.240.80 (0.39--1.63)0.53 TC or CC2942510.93 (0.75--1.14)0.480.92 (0.74--1.14)0.430.77 (0.57--1.04)0.09*IL6R*\
rs4537545 CC289247 CT3693241.03 (0.82--1.29)0.821.05 (0.83--1.32)0.711.07 (0.79--1.47)0.65 TT1171131.13 (0.83--1.54)0.441.18 (0.86--1.63)0.301.17 (0.76--1.79)0.48 CT or TT4864371.05 (0.85--1.30)0.641.08 (0.86--1.34)0.511.09 (0.81--1.47)0.55*IL10*\
rs1800872 CC482408 CA2582251.03 (0.83--1.29)0.791.01 (0.80--1.27)0.940.93 (0.68--1.26)0.63 AA35421.42 (0.89--2.26)0.141.35 (0.83--2.18)0.221.47 (0.79--2.73)0.22 CA or AA2932671.08 (0.87--1.33)0.501.05 (0.84--1.30)0.670.99 (0.74--1.33)0.95*IL10*\
rs3024505 CC518467 CT2212001.00 (0.80--1.26)0.971.01 (0.80--1.28)0.951.19 (0.87--1.61)0.28 TT22241.21 (0.67--2.19)0.531.32 (0.72--2.42)0.371.80 (0.79--4.12)0.16 CT or TT2432241.02 (0.82--1.27)0.841.04 (0.83--1.30)0.761.23 (0.92--1.66)0.17*IL12B*\
rs3212217 GG499460 GC2352000.92 (0.74--1.16)0.490.95 (0.75--1.19)0.640.94 (0.69--1.29)0.72 CC25210.91 (0.50--1.65)0.760.94 (0.51--1.72)0.840.57 (0.23--1.41)0.22 GC or CC2602210.92 (0.74--1.15)0.470.95 (0.76--1.19)0.630.91 (0.67--1.23)0.53*IL12B*\
rs6887695 GG385324 GC2933011.22 (0.98--1.52)0.071.24 (0.99--1.55)0.061.31 (0.97--1.77)0.07 CC72701.16 (0.81--1.66)0.431.16 (0.80--1.69)0.430.98 (0.59--1.61)0.94 GC or CC3653711.21 (0.98--1.49)0.071.22 (0.99--1.51)0.061.24 (0.93--1.64)0.14*IL12RB1*\
rs401502 CC360304 CG3033111.22 (0.98--1.51)0.081.21 (0.96--1.51)0.101.19 (0.88--1.61)0.26 GG87700.95 (0.67--1.35)0.790.97 (0.68--1.39)0.871.18 (0.74--1.88)0.48 CG or GG3903811.16 (0.94--1.42)0.171.15 (0.93--1.43)0.191.19 (0.89--1.58)0.24*IL17A*\
rs2275913 GG340307 GA3363010.99 (0.80--1.24)0.940.98 (0.79--1.23)0.890.90 (0.67--1.22)0.51 AA95840.98 (0.70--1.36)0.901.00 (0.71--1.40)0.981.00 (0.63--1.57)0.99 GA or AA4313850.99 (0.80--1.22)0.920.99 (0.80--1.22)0.890.92 (0.69--1.22)0.57*IL18*\
rs187238 GG387380 GC3122590.85 (0.68--1.05)0.130.83 (0.66--1.03)0.090.74 (0.55--1.00)0.049 CC64410.65 (0.43--0.99)0.040.69 (0.45--1.06)0.090.58 (0.32--1.04)0.07 GC or CC3763000.81 (0.66--1.00)0.04990.80 (0.65--0.99)0.040.71 (0.53--0.95)0.02*IL18*\
rs1946518 GG282259 GT3633290.99 (0.79--1.24)0.910.96 (0.76--1.21)0.710.89 (0.65--1.21)0.45 TT113970.93 (0.68--1.29)0.680.95 (0.68--1.31)0.740.80 (0.51--1.24)0.32 GT or TT4764260.97 (0.79--1.21)0.810.96 (0.77--1.19)0.680.86 (0.64--1.16)0.32*IL23R*\
rs11209026 GG680646 GA89500.59 (0.41--0.85)0.00450.63 (0.43--0.91)0.020.64 (0.38--1.05)0.08 AA511.00 (1.00--1.00)1.001.00 (1.00--1.00)1.001.00 (1.00--1.00)1.00 GA or AA94510.57 (0.40--0.82)0.00210.60 (0.42--0.87)0.010.63 (0.38--1.03)0.06*IFNG*\
rs2430561 TT199181 TA3983691.02 (0.80--1.30)0.881.01 (0.79--1.30)0.921.08 (0.77--1.52)0.65 AA1611390.95 (0.70--1.29)0.740.97 (0.71--1.32)0.851.09 (0.72--1.64)0.68 TA or AA5595081.00 (0.79--1.26)0.991.00 (0.79--1.27)0.991.08 (0.79--1.50)0.62*IFNGR1*\
rs2234711 TT290232 TC3613481.20 (0.96--1.51)0.111.20 (0.95--1.51)0.121.15 (0.84--1.57)0.40 CC1191081.13 (0.83--1.55)0.431.09 (0.79--1.50)0.601.11 (0.72--1.70)0.65 TC or CC4804561.19 (0.96--1.47)0.121.17 (0.94--1.46)0.161.14 (0.84--1.53)0.40*IFNGR2*\
rs8126756 TT553522 TC1681300.82 (0.63--1.06)0.130.83 (0.64--1.09)0.180.86 (0.60--1.24)0.42 CC18120.71 (0.34--1.48)0.360.69 (0.32--1.49)0.350.53 (0.18--1.54)0.24 TC or CC1861420.81 (0.63--1.04)0.090.82 (0.64--1.06)0.130.83 (0.59--1.17)0.28*IFNGR2*\
rs17882748 CC199173 CT3913411.00 (0.78--1.29)0.981.00 (0.77--1.30)0.991.01 (0.71--1.42)0.97 TT1531741.31 (0.97--1.76)0.081.31 (0.97--1.78)0.081.16 (0.77--1.73)0.48 CT or TT5445151.09 (0.86--1.38)0.481.09 (0.86--1.39)0.481.05 (0.76--1.45)0.76*TBX21*\
rs17250932 TT526497 TC2101790.90 (0.71--1.14)0.390.94 (0.74--1.19)0.610.84 (0.60--1.17)0.30 CC32190.63 (0.35--1.12)0.120.66 (0.36--1.19)0.170.37 (0.14--0.98)0.046 TC or CC2421980.87 (0.69--1.08)0.210.90 (0.72--1.14)0.390.78 (0.56--1.07)0.12*NLRP1*\
rs2670660 AA222202 AG3903280.92 (0.73--1.18)0.520.96 (0.75--1.23)0.731.12 (0.80--1.56)0.52 GG1541541.10 (0.82--1.47)0.531.11 (0.82--1.49)0.511.12 (0.75--1.67)0.59 AG or GG5444820.97 (0.78--1.22)0.821.00 (0.79--1.26)0.981.11 (0.81--1.52)0.50*NLRP1*\
rs878329 GG217206 GC3943330.89 (0.70--1.13)0.340.89 (0.69--1.14)0.350.99 (0.71--1.38)0.93 CC1551551.05 (0.79--1.41)0.731.05 (0.78--1.41)0.751.03 (0.69--1.54)0.90 GC or CC5494880.94 (0.75--1.17)0.570.93 (0.74--1.18)0.561.00 (0.73--1.36)0.98*NLRP3*\
rs10754558 CC294248 CG3553241.08 (0.86--1.36)0.501.06 (0.84--1.34)0.611.10 (0.81--1.51)0.54 GG1111161.24 (0.91--1.69)0.181.25 (0.91--1.71)0.171.11 (0.71--1.72)0.65 CG or GG4664401.12 (0.90--1.39)0.301.11 (0.89--1.38)0.361.11 (0.82--1.49)0.51*NLRP3*\
rs4612666 CC435360 CT2802771.20 (0.96--1.49)0.111.23 (0.99--1.54)0.071.28 (0.95--1.72)0.10 TT53481.09 (0.72--1.66)0.671.19 (0.78--1.82)0.411.07 (0.59--1.94)0.82 CT or TT3333251.18 (0.96--1.45)0.121.23 (0.99--1.52)0.061.24 (0.94--1.65)0.13*CARD8*\
rs2043211 AA321298 AT3423161.00 (0.80--1.24)0.970.98 (0.79--1.23)0.890.90 (0.67--1.22)0.50 TT94780.89 (0.64--1.25)0.520.89 (0.63--1.26)0.500.91 (0.57--1.44)0.68 AT or TT4363940.97 (0.79--1.20)0.800.96 (0.78--1.19)0.720.90 (0.67--1.19)0.45*JAK2*\
rs12343867 TT398358 TC2992630.98 (0.79--1.22)0.840.96 (0.76--1.20)0.690.82 (0.61--1.12)0.21 CC61651.18 (0.81--1.73)0.381.11 (0.75--1.63)0.611.03 (0.62--1.71)0.91 TC or CC3603281.01 (0.82--1.25)0.900.98 (0.79--1.21)0.860.86 (0.64--1.14)0.29Table 2Biological interpretation of the single nucleotide polymorphisms (SNPs) associated with ankylosing spondylitis (AS)GeneRs-numberPathwayModelOR (95% CI)*P*-value / Bonferroni^a^Effect of minor-alleleBiological interpretation*TLR1*rs4833095Pathogen recognitionCC vs TT2.59 (1.48--4.51)0.00081 / 0.04743C increase TLR1 level in PBMC \[[@CR56]\]Increased TLR1 level was associated with increased risk of AS. This could indicate that a genetically determined high activity of the NFkB pathway, and thus high TNF-α and IL-17 activity, was associated with increased risk of AS.*TLR4*rs1554973Pathogen recognitionCC vs TT0.55 (0.34--0.86)0.010 / 0.51Unknown \[[@CR67]\]--*LY96*rs11465996Pathogen recognitionGG vs CC0.68 (0.46--1.00)0.049 / 1.00-1625G increase MD-2 and TNF-α levels in human U937 cells and whole blood leukocytes \[[@CR57]\]Increased MD-2 and TNF-α level was associated with a reduced risk of AS. In contrast to the other results this indicate that genetically determined high TNF-driven inflammatory response was associated with reduced risk of AS.*TNF*rs1800629CytokinesGA or AA vs GG0.56 (0.44--0.72)0.0000047 / 0.00024-308A increase expression in jurkat cells \[[@CR65]\], reduce mRNA level in PBMC and serum \[[@CR48]\] or no association was found \[[@CR49]\]Reduced TNF-α mRNA level was associated with reduced risk of AS. This could indicate that genetically determined high TNF-driven inflammatory response was associated with increased risk of AS.*TNF*rs361525CytokinesGA or AA vs GG0.49 (0.31--0.78)0.0024 / 0.12-238A reduce expression in PBMC \[[@CR49]\]Reduced TNF-α expression was associated with reduced risk of AS. This indicates that genetically determined high TNF-driven inflammatory response was associated with increased risk of AS.*TNFRSF1A*rs4149570CytokinesGT or TT vs GG1.44 (1.15--1.80)0.0013 / 0.066^b^-609 T increase expression in PBMC \[[@CR50]\]Increased TNF-α receptor 1 expression was associated with increased risk of AS. This indicates that genetically determined high TNF-driven inflammatory response was associated with increased risk of AS.*PTPN22*rs2476601Immune responseGA or AA vs GG0.76 (0.58--0.98)0.037 / 1.001858A reduce TNF-α level in serum \[[@CR51]\]Reduced TNF-α level was associated with reduced risk of AS. This indicates that genetically determined high TNF-driven inflammatory response was associated with increased risk of AS.*IL18*rs187238CytokinesGC or CC vs GG0.80 (0.65--0.99)0.044 / 1.00-137C reduce IL-18 level in serum \[[@CR53]\] and expression in PBMC \[[@CR54]\]Reduced IL-18 expression, and thus reduced IL-17 and TNF-α activity, was associated with reduced risk of AS.\
This indicates that a genetically determined high activity of the IL23/IL17 pathway was associated with increased risk of AS.*IL23R*rs11209026CytokinesGA or AA vs GG0.60 (0.42--0.87)0.0071 / 0.36rs11209026A reduce IL-17 level in PBMC \[[@CR52]\]Reduced IL-17 level was associated with reduced risk of AS. This indicates that a genetically determined high activity of the IL23/IL17 pathway was associated with increased risk of AS.*OR* Odds ratio*95% CI* 95% confidence interval*PBMC* peripheral blood mononuclear cell^a^The Bonferroni calculations were based on the 51 SNPs assessed in this study^b^The *TNFRSF1A* (rs4149570) TT vs GG: OR: 1.79, 95% CI: 1.31--2.41, *p* = 0.00027, Bonferroni = 0.014

DNA extraction (Maxwell 16 LEV Blood DNA Kit; Promega, Madison, WI, USA) was performed as described by *Bank* et al. \[[@CR10]\]. For the healthy controls, DNA was extracted from EDTA-stabilized peripheral blood by either PureGene (Qiagen, Hilden, Germany) or Wizard Genomic (Promega, Madison, Wisconsin, USA) DNA purification kit according to the manufacturers\` instructions \[[@CR11]--[@CR17]\]. Competitive Allele-Specific Polymerase chain reaction (KASP™), an end-point PCR technology, was used by LGC Genomics for genotyping (LGC Genomics, Hoddesdon, United Kingdom) (<http://www.lgcgenomics.com/>).

Power calculation {#Sec5}
-----------------

The Genetic Power Calculator was utilized for power analysis of discrete traits (<http://zzz.bwh.harvard.edu/gpc/cc2.html>). The lowest minor allele frequency (MAF) of the studied SNPs was 0.10. The 'high-risk allele frequency' was set to 0.10, the 'prevalence' was set to 0.0018 \[[@CR18]\], D-prime was set to 1, type I error rate was set to 0.05 and number of cases and control:case ratio was 795:709. This cohort study had more than 80% chance of detecting a dominant effect with an odds ratio (OR) of 1.4 for AS.

Statistical analysis {#Sec6}
--------------------

Logistic regression was used to compare genotype distributions among patients with AS versus healthy controls. Crude odds ratio, odds ratio adjusted for age and sex, and odds ratio adjusted for age, sex, and smoking status were assessed (Table [1](#Tab1){ref-type="table"}). A chi-square test was used to test for deviation from Hardy-Weinberg equilibrium in the healthy controls and for haplotype analysis (Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}).Table 3Association of the *TLR2* haplotype combinations and risk of ankylosing spondylitis (AS). The haplotype combinations in *TLR2* described 93% of the genotypes observedHaplotype combinationsHaplotypesN~AS~ (%)N~Control~ (%)OR^a^(95% CI)*P*-valuers4696480 A \> Trs11938228 C \> Ars3804099 T\>C^b^11T:TA:AT:T69 (11)76 (10)1.00----22A:AC:CC:C72 (11)74 (10)1.070.68--1.700.8233A:AC:CT:T28 (4)34 (5)0.910.50--1.650.7644T:TC:CC:C14 (2)10 (1)1.520.64--3.700.3812T:AC:AC:T158 (24)197 (27)0.880.60--1.300.5513T:AC:AT:T76 (12)103 (14)0.810.52--1.260.3714T:TC:AC:T59 (9)49 (7)1.330.80--2.190.3123A:AC:CC:T77 (12)89 (12)0.950.61--1.490.9124T:AC:CC:C52 (8)55 (8)1.040.63--1.720.9034T:AC:CC:T51 (8)44 (6)1.280.76--2.140.43*OR* Odds ratio^a^OR was calculated for each haplotype combination by using the haplotype 11 as reference group^b^The variant allele of rs3804099T T \> C has been shown to decrease TNF-α, IL-1β & IL-6 level \[[@CR68]\]Table 4Association between *TLR4* haplotype combinations and risk of ankylosing spondylitis (AS). The haplotype combinations in *TLR4* described 94% of the genotypes observedHaplotype combinationsHaplotypesN~AS~ (%)N~Control~ (%)OR^a^(95% CI)*P*-valuers12377632\
T \> Crs1554973\
T \> Crs5030728\
G \> A11C:CT:TG:G95 (14)101 (14)1.00----22T:TT:TA:A69 (10)74 (10)0.990.64--1.531.0033T:TC:CG:G29 (4)57 (8)0.540.32--0.920.0344T:TT:TG:G3 (0)5 (1)0.640.15--2.740.7212T:CT:TG:A154 (23)188 (25)0.870.61--1.240.4713T:CT:CG:G126 (19)129 (17)1.040.72--1.510.8514T:CT:TG:G30 (5)32 (4)1.000.56--1.771.0023T:TT:CG:A99 (15)106 (14)0.990.67--1.471.0024T:TT:TG:A31 (5)24 (3)1.370.75--2.510.3634T:TT:CG:G28 (4)26 (4)1.140.63--2.090.76*OR* Odds ratioThe biological effect of the three polymorphisms in *TLR4* was unknown^a^OR was calculated for each haplotype combination by using the haplotype 11 as reference groupTable 5Association between *IL1B* haplotype combinations and risk of ankylosing spondylitis (AS). The haplotype combinations in *IL1B* described 97% of the genotypes observedHaplotype combinationsHaplotypesN~AS~ (%)N~Control~ (%)OR^a^(95% CI)*P*-valuers4848306\
-3737G \> A \[[@CR69], [@CR70]\]rs1143623\
-1464G \> C \[[@CR69], [@CR71]\]rs1143627\
-31 T \> C \[[@CR69], [@CR71], [@CR72]\]11A:AG:GT:T125 (18)148 (20)1.00----22G:GC:CC:C52 (8)54 (7)1.140.73--1.790.6533G:GG:GT:T32 (5)41 (5)0.920.55--1.550.7944G:GG:GC:C5 (1)3 (0)1.970.46--8.420.4812A:GG:CT:C163 (24)185 (24)1.040.76--1.430.8113A:GG:GT:T141 (20)147 (19)1.140.82--1.580.5014A:GG:GT:C44 (6)38 (5)1.370.84--2.250.2623G:GC:GC:T84 (12)92 (12)1.080.74--1.580.7024G:GC:GC:C28 (4)34 (4)0.980.56--1.701.0034G:GG:GT:C14 (2)16 (2)1.040.49--2.211.00*OR* Odds ratioThe variant allele of −3737 G \> A \[[@CR69]\], −1464 G \> C \[[@CR70]\] and − 31 T \> C \[[@CR71], [@CR72]\] have been shown to decrease IL-1β level \[[@CR69]--[@CR72]\]^a^OR was calculated for each haplotype combination by using the haplotype 11 as reference groupTable 6Association of the *TNF* haplotype combinations and risk of ankylosing spondylitis (AS). The haplotype combinations in *TNF* described 97% of the genotypes observedHaplotype combinationsHaplotypesN~AS~ (%)N~Control~ (%)OR^a^(95% CI)*P*-valuers361525 G\>A^b^rs1800629 G\>A^c^11G:GG:G523 (76)469 (61)1.00----22G:GA:A9 (1)25 (3)0.32(0.15--0.70)0.00512G:GG:A125 (18)210 (28)0.53(0.41--0.69)\< 0.000113G:AG:G26 (4)47 (6)0.50(0.30--0.81)0.00714G:AG:A4 (1)12 (2)0.30(0.10--0.93)0.05*OR* Odds ratio^a^OR was calculated for each haplotype combination by using the haplotype 11 as reference group^b^The variant allele of TNF -238A rs361525A G \> A has been shown to reduce expression of TNF-α \[[@CR49]\]^c^The variant allele of TNF -308A rs1800629 G \> A has been shown to reduce mRNA level \[[@CR48]\]

Statistical analyses were performed using STATA version 15 (StataCorp LP, College Station, TX, USA).

Results {#Sec7}
=======

Study population {#Sec8}
----------------

Among the patients with AS the median age was 32 years (SD: 11.5) and 68% (483/709) were males. The healthy controls had a median age of 43 years (SD: 11.5) and 52% (411/384) were males. Among the patients 37% (118/323), 23% (73/323), and 41% (132/323) and among the controls 26% (207/788), 24% (189/788), and 50% (392/788) were current smokers, former smokers and never smokers, respectively. HLA-B27 staus was available for 498 patients of which 83% (411/498) were positive. Sixty percent (427/709) of the patients were treated with anti-TNF.

The genotype distributions among the healthy controls deviated from Hardy-Weinberg equilibrium for *TLR1* (743 T \> C (rs4833095)) (*p* = 0.03), *TLR2* (− 16,934 A \> T (rs4696480)) (*p* = 0.02), *TLR4* (rs1554973 T \> C) (*p* = 0.03), *TLR9* (1174 G \> A (rs352139)) (*p* = 0.02) and *TGFB1* (− 509 C \> T (rs1800469)) (*p* = 0.02). After correction for multiple testing, all SNPs studied were in Hardy-Weinberg equilibrium.

Polymorphisms associated with susceptibility of AS {#Sec9}
--------------------------------------------------

In the age and sex adjusted analysis, the homozygous variant genotype of *TLR1* 743 T \> C (rs4833095) (OR: 2.59, 95% CI: 1.48--4.51, *p* = 0.0008) and the combined homozygous and the heterozygous variant genotypes of *TNFRSF1A* -609 G \> T (rs4149570) (OR: 1.44, 95% CI: 1.15--1.80, *p* = 0.001) were associated with increased risk of AS. The homozygous variant genotype of *TLR4* T \> C (rs1554973) (OR: 0.55, 95% CI: 0.34--0.86, *p* = 0.01) and *LY96--*1625 C \> G (rs11465996) (OR: 0.68, 95% CI: 0.46--1.00, *p* = 0.05), and the combined homozygous and the heterozygous variant genotypes of *TNF* -308 G \> A (rs1800629) (OR: 0.56, 95% CI: 0.44--0.72, *p* = 0.000005), *TNF* -238 G \> A (rs361525) (OR: 0.49, 95% CI: 0.31--0.78, *p* = 0.002), *PTPN22* 1858 G \> A (rs2476601) (OR: 0.76, 95% CI: 0.58--0.98, *p* = 0.04), *IL18*--137 G \> C (rs187238) (OR: 0.80, 95% CI: 0.65--0.99, *p* = 0.04), and *IL23R* G \> A (rs11209026) (OR: 0.60, 95% CI: 0.42--0.87, *p* = 0.01) were associated with reduced risk of AS (Table [1](#Tab1){ref-type="table"}).

After Bonferroni correction for multiple testing the homozygous variant genotype of *TLR1* 743 T \> C (rs4833095) (OR: 2.59, 95% CI: 1.48--4.51, *p* = 0.04) and *TNFRSF1A* -609 G \> T (rs4149570) (OR: 1.79, 95% CI: 1.31--2.41, p = 0.01) were associated with increased risk of AS and the combined homozygous and the heterozygous variant genotypes of *TNF* -308 G \> A (rs1800629) (OR: 0.56, 95% CI: 0.44--0.72, *p* = 0.0002) were associated with reduced risk of AS (Table [2](#Tab2){ref-type="table"}).

SNPs associated with AS and the biological effect of the SNPs are summarized in Table [2](#Tab2){ref-type="table"}.

Haplotype analysis {#Sec10}
------------------

Haplotype analyses of *TLR2*, *TLR4, IL1B* and *TNF* are shown in Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}, respectively.

The *TLR4* haplotype combination 33 (rs12377632TT, rs1554973CC and rs5030728GG) was associated with reduced risk of AS (OR: 0.54, 95% CI: 0.32--0.92, *p* = 0.03) compared to the haplotype combination 11. In *TNF* all haplotype combinations were associated with reduced risk of AS compared to the haplotype combination 11 (rs361525GG and rs1800629GG).

No associations were found for haplotype combinations of *TLR2* or *IL1B*.

Discussion {#Sec11}
==========

In this case-control study, polymorphisms in a: the TNF-α (*TNF* (rs1800629 and rs361525), *TNFRSF1A* (rs4149570), and *PTPN22* (rs2476601)), b: the IL23/IL17 (*IL23R* (rs11209026), and *IL18* (rs187238)), or c: the NFkB (*TLR1* (rs4833095), *TLR4* (rs1554973), and *LY96* (rs11465996)) pathways were associated with risk of AS.

The found assocaitions for *TNF* (rs1800629) \[[@CR19]--[@CR22]\], *TNFRSF1A* (rs4149570) \[[@CR23]\], and *IL23R* (rs11209026) \[[@CR24]--[@CR33]\] are in agreement with other case-control studies. Furthermore, Zhao et al. found that the variant allele of *NLRP3* (rs4612666) was associated with increased risk of AS in Chinese patients \[[@CR23]\]. In our study we found a trend for associations of the variant allele of *NLRP3* (rs4612666) with increased risk of AS (*p* = 0.06). However, our results are in contrast to a meta-analysis of the *PTPN22* (rs2476601) polymorphism that did not find an association with AS \[[@CR34]\]. Finally, we identified novel risk loci in *TNF* (rs361525), *IL18* (rs187238), *TLR1* (rs4833095), *TLR4* (rs1554973), and *LY96* (rs11465996) that need validation in independent cohorts.

Most of the SNPs assessed in our study have known biological effects thus allowing a biological interpretation of the observed associations based on increased or reduced gene activity as summarized in Table [2](#Tab2){ref-type="table"} \[[@CR35]--[@CR47]\]. The associations observed for the *TNF* (rs1800629 and rs361525) polymorphisms suggest that reduced TNF-α mRNA level and expression of TNF-α was associated with reduced risk of AS \[[@CR48], [@CR49]\]. This is supported by our haplotype analysis which also suggests that the variant alleles of *TNF* rs1800629 and rs361525 were associated with reduced risk of AS. Likewise, the associations observed for the *TNFRSF1A* (rs4149570) polymorphism indicates that increased expression of the TNF-α receptor 1 was associated with increased risk of AS \[[@CR50]\]. Furthermore, the associations observed for the *PTPN22* (rs2476601) polymorphism suggests that reduced TNF-α serum level was associated with reduced risk of AS \[[@CR51]\]. Taken together, this suggests that genetically determined high activity of the TNF-α pathway was associated with increased risk of AS.

IL-17 is known to induce the production of many cytokines including TNF-α \[[@CR6]\]. IL-18 is a pro-inflammatory cytokine known to enhance the production of IL-17, TNF-α, and IL-1β \[[@CR8]\]. In this study, the association observed for the *IL23R* (rs11209026) polymorphism suggests that reduced IL-17 serum level, and thus reduced TNF-α activity, was associated with reduced risk of AS \[[@CR52]\]. Furthermore, the associations observed for the *IL18* (rs187238) polymorphism indicates that reduced IL-18 expression, and thus reduced IL-17 and TNF-α activity, was associated with reduced risk of AS \[[@CR53], [@CR54]\]. The associations found in the *IL23R* (rs11209026) and the *IL18* (rs187238) polymorphisms thus suggest that a genetically determined high activity of the IL23/IL17 pathway was associated with increased risk of AS. The two SNPs furthermore support that genetically determined high activity of the TNF-α pathway was associated with increased risk of AS. The observed associations between the polymorphisms in *IL23R* and *IL18* and risk of AS are in line with previous studies pointing out the IL23/IL17 pathway as central to the pathophysiology of AS \[[@CR3], [@CR4], [@CR55]\].

This study also suggests that the NFkB pathway may be involved in the etiology of AS. The associations observed for the *TLR1* (rs4833095) polymorphism suggests that increased TLR1 level was associated with increased risk of AS \[[@CR56]\]. High level of TLR1 may lead to increased NFkB activation and thus increased TNF-α and IL-17 activity, which is in line with the other results. However, in contrast to the other results*,* the associations observed for the *LY96* (rs11465996) polymorphism suggests that increased MD-2 (*LY96)* and TNF-α level was associated with a reduced risk of AS \[[@CR57]\]. Finally, the *TLR4* (rs1554973) polymorphism was associated with reduced risk of AS which was supported by the haplotype results (Table [4](#Tab4){ref-type="table"}). The biological effect of the *TLR4* (rs1554973) polymorphism is unknown, however, the result supports the notion that the NFkB pathway may be involved in the etiology of AS.

Both TNF-α \[[@CR58]\] and interleukin-17 inhibitors \[[@CR59]\] have been shown to reduce inflammation and improve symptoms in patients with AS \[[@CR60]\]. Furthermore, increased levels of TNF-α, IL-17, IL-23, IL-1β, and IL-6 have been found in sera and synovial fluid from AS patients \[[@CR61]--[@CR64]\]. The genetic associations between AS and the polymorphisms in *TLR1*, *TLR4*, *LY96*, *TNF*, *TNFRSF1A*, *IL18*, and *IL23R* found in this study, could potentially -- in part -- explain this altered cytokine milieu present in AS patients.

There are aspects of this study which should be interpreted with care. Conflicting results have been reported for the *TNF* (rs1800629) polymorphism \[[@CR48], [@CR49], [@CR65]\]. Furthermore, the *TNF* polymorphisms, as well as the HLA-B27 locus, are located on chromosome 6, and there is a risk that even a minor linkage disequilibrium could have confounded our results \[[@CR2]\]. *TLR1* (rs4833095), *TLR2* (rs4696480), *TLR4* (rs1554973), *TLR9* (rs352139), and *TGFB1* (rs1800469) were not in Hardy-Weinberg equilibrium among the healthy controls. Due to the number of polymorphisms analyzed this is probably a type II error. The polymorphisms do not deviate from Hardy-Weinberg equilibrium when corrected for multiple testing. We cannot exclude that some of our positive findings may be due to chance due to the obtained *p*-values and the number of statistical tests performed. When the results were corrected for multiple testing only the variant allele of *TLR1* (rs4833095) and *TNFRSF1A* (rs4149570) were associated with increased risk of AS and the variant allele of *TNF* (rs1800629) was associated with reduced risk of AS.

A major strength of this study was that the cohort was rather large including 709 patients with AS and 795 healthy controls and the associations that we report were biologically plausible. Also, the validity of the diagnosis is expected to be high, since the patients were identified via a clinical database that the rheumatologist use for prospective monitoring of patients as part of routine care \[[@CR66]\].

Conclusions {#Sec12}
===========

In conclusion, we replicated associations between AS and the polymorphism *TNF* (rs1800629), *TNFRSF1A* (rs4149570), and *IL23R* (rs11209026). Furthermore, we identified novel risk loci in *TNF* (rs361525), *IL18* (rs187238), *TLR1* (rs4833095), *TLR4* (rs1554973), and *LY96* (rs11465996) that need validation in independent cohorts. The results suggest that genetically determined high activity of the TNF-α, IL23/IL17, and NFkB pathways increase the risk of AS.
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